CDC reports 10,772 confirmed Ebola cases and 5234 deaths, making this the second-largest outbreak on record. Kenya and Nigeria have reported cases.
|Videos|March 7, 2016
Zika Virus and Community Pharmacists
Author(s)Contagion Editorial Staff
Jason C. Gallagher, PharmD, shares some key things that community pharmacists need to know about the Zika virus and the current outbreak.
Advertisement
Contagion® speaks with Jason C. Gallagher, PharmD, FCCP, BCPS, Clinical Professor at the Temple University School of Pharmacy and a Clinical Pharmacy Specialist in Infectious Diseases at Temple University Hospital about the Zika virus and key things that community pharmacists need to know about the Zika virus and the current outbreak.
Advertisement
Related to this article
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Advertisement
Advertisement